Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

Wangkahart, Eakapol; Thongsrisuk, Areerat; Vialle, Regis; Pholchamat, Sirinya; Sunthamala, Phitcharat; Phudkliang, Janjira; Srisapoome, Prapansak; Wang, Tiehui; Secombes, Christopher J.

doi:10.1016/j.fsi.2023.108563

Cited by 16 publications

(9 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, our findings showed no recorded internal lesions in vaccinated fish several weeks post-vaccination. This information was consistent with that described by Wangkahart et al (2023), who recently reported normal internal organs of Nile tilapia with no adhesions at the 5th WPV with an inactivated whole-cell vaccine against S. agalactiae adjuvanted using Montanide™ ISA 763 A VG or ISA 763 B VG.…”

Section: Discussionsupporting

confidence: 92%

“…Regarding the persistence of the tested adjuvants, assessment of the adjuvant quality can depend upon its persistence in the tissues of vaccinated fish at different time points. This is an important factor in choosing the best quality adjuvant for application, with no noticeable negative impacts on the vaccinated fish (Wangkaghart et al 2021;Wangkahart et al 2023). In this context, our findings showed no recorded internal lesions in vaccinated fish several weeks post-vaccination.…”

Section: Discussionsupporting

confidence: 48%

See 1 more Smart Citation

Efficacy of combined inactivated vaccines against Vibrio alginolyticus and Streptococcus agalactiae infections in Nile tilapia in Egypt

et al. 2023

View full text Add to dashboard Cite

Vibrio alginolyticus and Streptococcus agalactiae are important bacterial pathogens that yielded high losses in Nile tilapia in Egypt. The present study aimed to check the protective efficacy of inactivated whole-cell bivalent vaccines against these pathogens using incomplete Freund’s adjuvant and Montanide™ IMS 1312 VG as adjuvants. The antibody titers have been determined at different weeks post-vaccination (WPV). Moreover, the protection levels against the challenged bacterial pathogens have also been examined in relation to the time-dependent protection at different WPV. The results revealed that serum antibodies were generated in all immunized fish at 1st WPV, peaked at 4th WPV, continued, and gradually decreased from 6th WPV to 14th WPV in all vaccinated groups. In addition, vaccines induced significantly higher protection of the immunized tilapia, manifested by higher survival rates. We noticed that the antibody levels and survival rates of the vaccinated fish by a vaccine adjuvanted by Montanide™ IMS 1312 VG were higher than those produced by a vaccine adjuvanted by incomplete Freund’s adjuvant at different time points. Moreover, no external clinical signs, visceral adhesions, or internal lesions were recorded in the vaccinated tilapia, demonstrating the safety of the formulated vaccines. According to the aforementioned findings, we could suggest that the prepared bivalent vaccines, using the two adjuvant types, are safe and highly protective and could be utilized as promising candidate vaccines to increase the resistance of Nile tilapia against V. alginolyticus and S. agalactiae infections. Moreover, Montanide™ IMS 1312 VG enhanced the immuno-protectivity and exhibited optimum immune response and earlier protection compared to the vaccine adjuvanted by incomplete Freund’s adjuvant, demonstrating its added value during the preparation of tilapia vaccines.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 48%

Efficacy of combined inactivated vaccines against Vibrio alginolyticus and Streptococcus agalactiae infections in Nile tilapia in Egypt

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is important to note that different adjuvants can be combined with different antigens and provide different types and scales of immunostimulation, ultimately leading to totally different immunization outcomes conferred as well [105][106][107]. Thus, the meticulous selection of the adjuvantantigen combination stands out as an important parameter during the development and formulation of a new vaccine, even in the context of aquaculture.…”

Section: The Current State Of Adjuvants In Aquaculture Vaccinologymentioning

confidence: 99%

Transforming Aquaculture Through Vaccination: A Review on Recent Developments and Milestones

Tammas,

Bitchava,

Gelasakis

2024

Preprint

View full text Add to dashboard Cite

Aquaculture has rapidly emerged as one of the fastest growing industries, expanding both on global and on national fronts. With the ever-increasing demand for high biological value protein, the aquaculture industry has established itself as one of the most efficient forms of animal production, proving to be a vital component of global food production, by supplying nearly 50% of the planet’s seafood. As in classic animal production, the prevention of diseases constitutes an enduring challenge associated with severe economic and environmental repercussions. Nevertheless, remarkable strides in the development of aquaculture vaccines have been recently witnessed, offering sustainable solutions to persistent health-related issues challenging resilient aquaculture production. These advancements are characterized by breakthroughs in increased species-specific precision, improved vaccine delivery systems, and innovations in vaccine development, following the recent advent of nanotechnology, biotechnology, and artificial intelligence in the -omics era. The objective of this paper was to assess recent developments and milestones revolving around aquaculture vaccinology and provide an updated overview of strengths, weaknesses, opportunities, and threats of the sector, by incorporating and comparatively discussing various diffuse advances that span across a wide range of topics, including emerging vaccine technologies, innovative delivery methods, insights on novel adjuvants, and parasite vaccine development for the aquaculture sector.

show abstract

“…Application of the vaccine by injection was safe for the fish. 2 weeks after injection, no mortality was recorded in either group, and no abnormalities were observed through the observation period to responses of the inactivated S. agalactiae whole cell vaccine (SAIV) prepared and compounded with either of the two adjuvants [13]. Vaccination treatment can stimulate a higher serum antibody titer than the control [3].…”

Section: Mediamentioning

confidence: 99%

Development of freeze-dried bivalent fish vaccine product with skimmed milk as stabiliser

Sugiani,

Lusiastuti,

Sumiati

et al. 2023

E3S Web Conf.

View full text Add to dashboard Cite

Bacterial vaccines have been tested for their effectiveness in protecting fish from potential virulent diseases. The current vaccine preparations are mostly in liquid form, which affects prices due to an increase in the cost of shipment, the stability of liquid products also has limitations in long-term storage. This study aims to develop a method of preparation of bivalent vaccine through freeze dry method with skimmed milk as a filler for optimization of the vaccine products. The preparation of bivalent vaccine by freeze dry method can reduce 96.67% of total weight compared to vaccines in liquid form. The quality test showed that bivalent vaccine products by freeze dry method with skimmed milk filler containing bacteria Aeromonas hydrophila and Streptococcus agalactiae are passed the sterility and viability test. The application of the vaccine can provide a positive response to increase the antibody titer and other hematological parameter responses and increase the survival rate of fish. The development of freeze-dried vaccine products can optimize fish vaccines as a recommended product in fish disease management.

show abstract

Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

Cited by 16 publications

References 73 publications

Efficacy of combined inactivated vaccines against Vibrio alginolyticus and Streptococcus agalactiae infections in Nile tilapia in Egypt

Efficacy of combined inactivated vaccines against Vibrio alginolyticus and Streptococcus agalactiae infections in Nile tilapia in Egypt

Transforming Aquaculture Through Vaccination: A Review on Recent Developments and Milestones

Development of freeze-dried bivalent fish vaccine product with skimmed milk as stabiliser

Contact Info

Product

Resources

About